Depression treatment has traditionally arrived in familiar packages: a prescription bottle, a therapist’s office, or a clinic-based brain-stimulation session. The Flow FL-100 adds a distinctly modern option to that lineupa lightweight headset that delivers a very low direct electrical current through the forehead while the user sits at home. It sounds a little like science fiction, minus the chrome jumpsuit and suspiciously dramatic lighting.
The important phrase, however, is not “electric headset.” It is prescription medical device. The U.S. Food and Drug Administration approved the Flow FL-100 in December 2025 for certain adults with moderate to severe major depressive disorder. It may be prescribed on its own or alongside medication or psychotherapy, but it is not intended as a do-it-yourself mood gadget, an emergency treatment, or a reason to stop existing care without medical guidance.
Here is what the Flow depression headset does, what the clinical trial actually found, where the evidence remains uncertain, and what using low-current transcranial direct current stimulation may feel like in everyday life.
What Is the Flow FL-100 Depression Headset?
The Flow FL-100 is a home-use neuromodulation device that provides transcranial direct current stimulation, usually shortened to tDCS. Two saline-soaked electrode pads rest against the forehead and deliver a current of 2 milliamps. For perspective, that is a tiny current; the goal is to influence the excitability of networks near the brain’s surface, not to create a seizure or “shock” someone into feeling better.
The headset pairs with a smartphone app that guides placement, starts and pauses sessions, and records treatment use. A clinician can remotely monitor the schedule through a patient-management platform. The FDA-labeled program begins with five 30-minute sessions per week for three weeks, followed by up to three sessions per week. Only one session is permitted per day.
Who the FDA Approval Covers
The approval applies to adults age 18 and older who are experiencing a current episode of moderate to severe major depressive disorder and are not considered treatment refractory to medication. In plain English, the labeled population does not include people whose depression has already been classified as resistant after multiple adequate medication trials.
Flow may be used as monotherapy, meaning without another active depression treatment, or as an adjunct to an antidepressant or psychotherapy. That flexibility is useful, but it should not be confused with universal suitability. Depression is not one tidy condition with one tidy switch, and a clinician still has to consider diagnosis, severity, bipolar symptoms, suicide risk, other medical conditions, and current treatments.
How Can a Low Electrical Current Affect Depression?
The electrodes are positioned to send current across the left and right dorsolateral prefrontal cortex, regions involved in attention, motivation, planning, emotional regulation, and broader mood-related networks. The anode sits over the left side and is intended to increase cortical excitability, while the cathode sits over the right side and has an opposing modulatory effect.
Scientists do not describe tDCS as forcing neurons to fire like tiny electrical fireworks. A better explanation is that it slightly changes the resting electrical environment of cortical cells, making some patterns of activity more or less likely. Repeated sessions may support longer-term changes in network connectivity and neuroplasticity. The exact antidepressant mechanism is still being studied, and results can vary according to electrode placement, dose, session frequency, duration, supervision, and patient characteristics.
tDCS Is Not ECTand It Is Not TMS
Because all three treatments involve the brain, they are often tossed into the same conversational blender. They are very different.
Electroconvulsive therapy, or ECT, is performed under anesthesia and deliberately produces a brief controlled seizure. Transcranial magnetic stimulation, or TMS, uses magnetic pulses from a clinic-based coil to stimulate targeted brain tissue. Flow’s tDCS uses a continuous, low-intensity electrical current through scalp electrodes. It requires no anesthesia and is designed for home use under a clinician’s supervision. Calling all three “electric therapy” is a bit like calling a desk fan, a jet engine, and a hair dryer the same machine because air comes out.
What Did the Main Flow FL-100 Clinical Trial Find?
The FDA decision relied heavily on the Empower study, a fully remote, two-site randomized trial involving 174 adults in the United States and the United Kingdom. Participants had at least moderate major depression. Some were receiving a stable antidepressant or stable psychotherapy, while others were not receiving either treatment.
Half received active 2-milliamp stimulation, and half received sham treatment designed to create brief initial sensations without continuing the therapeutic current. Participants completed five sessions per week for the first three weeks and three sessions per week for another seven weeks. The blinded phase therefore lasted 10 weeks and included up to 36 sessions.
The Primary Result Was Positive, but the Difference Was Modest
On the 17-item Hamilton Depression Rating Scale, active treatment improved symptoms by an average of 9.4 points, compared with 7.1 points in the sham group. The average difference between groups was 2.3 points. That result was statistically significant, meaning it was unlikely to be explained by chance under the study’s assumptions.
Response and remission results looked more dramatic. Using the Hamilton scale, 54.4% of the active group met the response definition, compared with 26.9% of the sham group. Remission occurred in 44.9% of the active group and 21.8% of the sham group. On another clinician-rated measure, the Montgomery-Åsberg Depression Rating Scale, remission rates were 57.5% with active treatment and 29.4% with sham.
That explains why readers may see both “about 45%” and “about 58%” reported as the remission rate. They come from different validated rating scales, not from a numerical magic trick performed by the marketing department.
Why the FDA Still Described Uncertainty
FDA approval does not mean every scientific question has been settled. The agency said the likely benefit outweighed the likely risks, while also describing a moderate level of uncertainty. Among its concerns were possible unblindingparticipants may have guessed whether they received active stimulation because tingling and skin effects were more noticeablethe absence of a prespecified threshold for a clinically meaningful Hamilton-scale difference, and conflicting findings in the broader tDCS literature.
That last point matters. A separate 2024 randomized trial of 210 adults found that fully unsupervised home tDCS, with or without a digital psychological program, did not outperform sham treatment after six weeks. Differences in supervision, treatment duration, protocol, device setup, and study populations may help explain the disagreement, but they do not make the negative trial disappear.
The honest conclusion is that home-based tDCS is promising and now has an FDA-approved device for a defined population, yet it is not a guaranteed antidepressant and the evidence base continues to evolve.
What Are the Side Effects and Safety Concerns?
In the pivotal study, the Flow FL-100 was generally well tolerated, and no serious adverse event was attributed to the device. The most common problems were local and temporary: skin redness, dryness, irritation, tingling, itching, stinging, warmth, or a mild burning sensation beneath the electrodes. Headache and difficulty concentrating during a session can also occur.
Skin burns have been reported when electrode pads were reused or allowed to dry out. The FDA instructions therefore require a fresh pair of saline pads for every session. Makeup, hair products, damaged skin, and incorrect placement can also interfere with contact and increase irritation. This is one area where “reduce, reuse, recycle” should politely wait outside.
Who Should Not Use It or Needs Extra Review?
The labeled contraindications include open wounds, broken or damaged skin at the electrode site and metallic skull reconstruction at that location. Patients should discuss extra precautions with a clinician if they are pregnant, have current thoughts of suicide or self-harm, have a seizure disorder or unexplained loss of consciousness, have metal or implanted devices in or around the brain, or have a chronic skin condition affecting the forehead or scalp.
Published tDCS literature has also identified mania or hypomania as a potential risk. That is especially relevant when a person’s apparent “depression” may be part of bipolar disorder. New agitation, unusually elevated mood, sharply reduced need for sleep, impulsive behavior, worsening depression, or suicidal thinking should prompt immediate clinical contact rather than a heroic attempt to finish the week’s sessions.
How Does Flow Fit With Medication and Talk Therapy?
For many people, antidepressant medication and evidence-based psychotherapy remain the most accessible first treatments. They also have a much larger body of long-term evidence. Flow’s appeal is that it offers a nondrug option without the travel demands of clinic-based stimulation. It may be particularly attractive to someone who worries about medication side effects, prefers a device-based approach, or needs another option that can be used alongside existing care.
Still, “medication-free” should not automatically be translated as “side-effect-free,” “more natural,” or “better.” Electricity is perfectly natural; lightning is also natural and remains a poor wellness strategy. The sensible comparison is whether a treatment’s expected benefit, risks, cost, convenience, and evidence fit the individual patient.
Flow is also not a fast substitute for ECT when depression is life-threatening, nor is it labeled for treatment-resistant depression in the same way many people encounter TMS. Severe inability to eat or drink, psychosis, catatonia, imminent suicide risk, or rapid deterioration calls for urgent medical assessment and may require a faster, more intensive treatment setting.
Is the Flow FL-100 Available in the United States?
As of June 2026, the device has FDA premarket approval but is not yet broadly available to U.S. patients. Flow Neuroscience says the U.S. launch is planned for September 1, 2026. It will be a prescription-only product, so consumers should expect a clinical evaluation rather than a simple “add to cart and stimulate” checkout experience.
Pricing, insurance coverage, replacement-pad costs, telehealth requirements, and prescribing pathways may differ when commercial distribution begins. Patients considering the device should ask who monitors treatment, how symptom changes are measured, what happens if the device is ineffective, and whether follow-up care is included in the price.
What Using the Flow FL-100 May Feel Like: Practical Experience
The following is not a first-person product review or a promise that every user will have the same experience. It is a realistic picture drawn from the treatment protocol, reported adverse effects, and the practical demands of home neuromodulation.
The First Session: More Setup Than Drama
A first session will probably feel less like entering a futuristic laboratory and more like learning a new kitchen appliance while an app watches your forehead. The user opens a fresh pair of saline pads, attaches them to the headset, clears hair and cosmetics away from the contact area, adjusts the metal band, and checks positioning with the app. The current gradually ramps up rather than arriving with a cinematic zap.
Mild tingling, itching, warmth, or prickling may be noticeable under the pads. Some people adapt to the sensation within minutes; others remain aware of it throughout the session. Severe burning is not something to “push through.” The instructions advise pausing or stopping treatment and speaking with the clinician when sensations become intense, when headaches persist, or when tinnitus develops.
The First Three Weeks: Routine Is the Real Assignment
Five 30-minute sessions each week sounds manageable on paper. In real life, it means finding five quiet windows, preparing the skin, opening new pads, keeping the phone charged, maintaining Bluetooth connectivity, cleaning the electrodes, and remembering that depression itself can make routines unusually difficult. The device may be portable, but the treatment still asks for consistency.
Some users may schedule sessions with morning coffee, after work, or during a calm television program. Activities that cause the headset to shift are a bad idea, so this is not the moment for burpees, ambitious vacuuming, or interpretive dance. A stable chair and a predictable time can make adherence easier.
Improvement May Show Up Quietly
Antidepressant change does not always arrive as a sudden burst of happiness. Early improvement may look like getting out of bed with less negotiation, replying to a message, showering without treating it as an expedition, concentrating for another 20 minutes, or feeling slightly more interested in food or conversation. Because daily mood fluctuates, weekly symptom scales and functional observations may be more useful than asking, “Do I feel cured today?”
The Empower trial assessed outcomes over 10 weeks, not after one or two sessions. A user should therefore expect monitoring over time rather than instant judgment. At the same time, a clinician may want to review treatment sooner if symptoms worsen, side effects interfere with use, or adherence becomes impossible.
Not Feeling Better Is Also a Possible Experience
Even in the positive pivotal trial, a substantial share of participants did not achieve remission. Some people may notice partial improvement, some may improve only while also using medication or psychotherapy, and some may experience no meaningful benefit. Nonresponse is not a failure of willpower, app technique, or moral character. It is information that helps a clinician choose the next step.
This is also why personal testimonials should be treated as stories rather than statistics. A glowing review can be sincere and still say little about how another person will respond. Depression studies often show improvement in sham groups because symptoms can fluctuate, people receive attention and monitoring, expectations matter, and other treatments continue.
The best personal “experience report” is therefore a structured record shared with a clinician: sessions completed, symptom scores, sleep, energy, function, adverse effects, medication changes, and safety concerns.
Living With a Device-Based Treatment
For the right patient, the biggest benefit may be logistical. A home treatment avoids repeated drives to a stimulation clinic and may fit around work, caregiving, mobility limitations, or rural living. The trade-off is greater responsibility for correct setup and honest symptom reporting. Remote care works best when “remote” does not become “alone.”
A good treatment plan should include scheduled clinical check-ins, clear instructions for missed sessions, a method for reporting side effects, and a safety plan for worsening mood. The headset can deliver current; it cannot notice a change in someone’s voice, arrange emergency care, or replace the human relationship that often helps depression treatment succeed.
Conclusion: A Meaningful New Option, Not a Miracle Helmet
The Flow FL-100 marks an important change in U.S. depression care: it is the first FDA-approved home-use tDCS device specifically indicated for moderate to severe major depressive disorder in a defined adult population. Its pivotal trial found better average symptom improvement, response, and remission than sham treatment, and its physical side effects were generally mild and temporary.
The balanced view is more useful than either hype or dismissal. The benefits were modest on the primary symptom score, other home-tDCS research has produced negative results, and the FDA explicitly acknowledged uncertainty. Flow may become a valuable standalone or add-on treatment for some adults, especially when home access matters, but it requires a prescription, clinical supervision, correct pad use, and realistic expectations.
